AGE-SPECIFIC, PROSTATE-SPECIFIC ANTIGEN (PSA) RANGES IN AFRICAN AMERICANS

前列腺癌是目前最常见的癌症诊断和排名 仅次于肺癌，是美国男性死亡的根本原因。 美国的 目前对前列腺癌控制的关注 致力于早期发现和干预。 自1987年以来， 血清前列腺特异性抗原（PSA）的测量导致了显着的 前列腺癌的检测增加，大概在早期 阶段和年轻的年龄。 最近的研究表明， 外周血中不同分子形式的血清PSA的测定 循环，或根据患者年龄校正PSA值，可能会提高其 然而，我们对这些诊断特征的大部分知识， 标记是基于高加索人群的。 而发病率和 前列腺癌的死亡率在非洲 美国人比北美白人多，目前尚不清楚血清 PSA应该用于非裔美国人。 我们假设 年龄特异性参考范围和PSA的分子形式将相似 北美非裔美国人和白人（零假设）。 测试 这是一个随机抽取的大约500名健康的非裔美国人的样本， 40-79岁（含），居住在密歇根州杰内塞县，将 被要求参加一项以社区为基础的横断面研究， 将确定血清前列腺特异性 抗原（PSA）。 游离和复合PSA的年龄特异性分布， 将评估PSA密度（PSA/前列腺体积）。 每例受试者 将评估梗阻性尿路症状，并通过 直肠指诊（DRE）和经直肠超声检查（TRUS）。 之前 预定的临床检查，将在家中进行面谈 每个参与者使用标准化的预测试问卷， 将收集有关前列腺癌可能风险因素的信息， 良性前列腺增生（BPH）。 在临床的时候， 检查时，将获得额外的血液样本并准备用于 冷冻储存，以预测未来的流行病学调查。 这些研究将确定血清PSA，PSA的新分子形式， 和PSA密度应在非裔美国人中解释。

Prostate cancer is currently the most common cancer diagnosed and ranks second after lung cancer as the underlying cause of death among men in the United States. Current concerns about the control of prostate cancer have been directed toward early detection and intervention. Since 1987, the measurement of serum prostate-specific antigen (PSA) has led to dramatic increases in the detection of prostate cancer, presumably at earlier stages and at younger ages. Recent work has suggested that the measurement of different molecular forms of serum PSA in the peripheral circulation, or correcting PSA values for patient age, may enhance its diagnostic characteristics, however, most of our knowledge of these markers is based on Caucasian populations. Whereas the incidence and mortality rates of prostate cancer are significantly higher among African Americans than North American whites, it is currently unknown how serum PSA should be used in African-American men. It is our hypothesis that age-specific reference ranges and molecular forms of PSA will be similar in North American African Americans and whites (null hypothesis). To test this a random sample of approximately 500 healthy African-American men, 40-79 years of age inclusive, residing in Genesee County, Michigan, will be asked to participate in a cross-sectional, community-based study that will determine appropriate reference ranges for serum prostate-specific antigen (PSA). The age-specific distribution of free and complexed PSA, and PSA density (PSA/prostatic volume) will be assessed. Each subject will be evaluated for obstructive urinary tract symptoms, and examined by digital rectal (DRE) and transrectal ultrasonography (TRUS). Prior to the scheduled clinical examination, an interview will be conducted in the home of each participant using a standardized pre-tested questionnaire that will gather information on possible risk factors for prostate cancer and benign prostatic hyperplasia (BPH). At the time of the clinical examination, additional blood samples will be obtained and prepared for frozen storage in anticipation of future epidemiologic investigations. These studies will establish how serum PSA, new molecular forms of PSA, and PSA density should be interpreted in African Americans.